Plain-English translation of NCT07225946 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 3 — Testing in thousands of people, comparing the treatment against what doctors currently use. This is the last big step before approval.
This clinical trial is testing a new immunotherapy drug called combined with a standard chemotherapy drug () to treat advanced prostate cancer that no longer responds to hormone-blocking medications. Researchers want to see if adding this medication to chemotherapy helps slow or stop cancer growth better than chemotherapy alone. The study will compare outcomes in about 800 men with this type of cancer.
Many men with advanced prostate cancer eventually develop resistance to hormone-blocking drugs, meaning their cancer continues to grow despite treatment. This trial exists to find out whether this new immunotherapy medication can help fight back against the cancer when combined with chemotherapy, potentially giving patients a more effective treatment option.
You likely qualify if…
You likely don't qualify if…
If you join this study, you will be randomly assigned to receive either the new medication plus chemotherapy, or chemotherapy alone with a standard steroid medication. You will receive your assigned treatment through regular clinic visits until your cancer progresses, you experience unacceptable side effects, or the study ends. Your doctors will monitor your progress with imaging scans and blood tests throughout the study to measure how well the treatment is working.
AI-generated summary from trial data · Aug 29, 2026 · Not medical advice
United States